

This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, is available on [our website](#) and various professional platforms.

On December 15, 2020, SanBio Co., Ltd. announced earnings results for Q3 FY01/21; see the results section for details.

Cumulative (JPYmn)	FY01/19				FY01/20				FY01/21				FY01/21	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	% of FY	1H Est.	
Operating revenue	158	416	569	742	189	428	424	447	-	-	-	-	-	
YoY	27.9%	66.3%	53.2%	51.2%	19.5%	2.9%	-25.4%	-39.7%	-	-	-100.0%	-	-	
Operating expenses	1,163	2,031	3,048	4,476	1,438	2,813	4,053	5,933	1,242	2,571	4,188	-	-	
YoY	1.5%	-15.3%	-13.9%	-8.1%	23.7%	38.5%	33.0%	32.6%	-13.6%	-8.6%	3.3%	-	-	
Operating expenses / Operating revenue	733.8%	488.8%	535.8%	603.5%	759.4%	657.6%	955.2%	1,326.7%	-	-	-	-	-	
R&D expenses	972	1,669	2,497	3,721	1,096	2,014	2,862	4,328	857	1,799	2,974	-	-	
YoY	4.7%	-16.6%	-16.8%	-10.5%	12.7%	20.6%	14.6%	16.3%	-21.8%	-10.7%	3.9%	-	-	
Other operating expenses	190	362	551	754	343	799	1,191	1,606	385	772	1,214	-	-	
YoY	-12.1%	-9.0%	1.9%	5.9%	80.0%	120.6%	116.1%	112.8%	12.4%	-3.4%	1.9%	-	-	
Operating profit	-1,004	-1,616	-2,479	-3,734	-1,249	-2,385	-3,629	-5,486	-1,242	-2,571	-4,188	-	-2,710	
YoY	-	-	-	-	-	-	-	-	-	-	-	-	-	
OPM	-	-	-	-	-	-	-	-	-	-	-	-	-	
Recurring profit	-836	-1,040	-1,548	-2,920	-727	-2,040	-3,271	-5,147	-1,506	-3,206	-4,840	-	-2,759	
YoY	-	-	-	-	-	-	-	-	-	-	-	-	-	
RPM	-	-	-	-	-	-	-	-	-	-	-	-	-	
Net income	-838	-1,042	-1,549	-2,921	-736	-2,049	-3,281	-5,158	-1,507	-3,207	-4,842	-	-2,760	
YoY	-	-	-	-	-	-	-	-	-	-	-	-	-	
Net margin	-	-	-	-	-	-	-	-	-	-	-	-	-	

Quarterly (JPYmn)	FY01/19				FY01/20				FY01/21				FY01/21	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	% of FY	FY Est.	
Operating revenue	158	257	153	173	189	238	-3	23	-	-	-	-	-	
YoY	27.9%	104.0%	26.3%	44.9%	19.5%	-7.3%	-102.2%	-86.8%	-	-	-	-	-	
SG&A expenses	1,163	869	1,017	1,427	1,438	1,375	1,240	1,880	1,242	1,329	1,617	-	-	
YoY	1.5%	-30.7%	-10.9%	7.5%	23.7%	58.3%	22.0%	31.7%	-13.6%	-3.3%	30.4%	-	-	
Operating expenses / Operating revenue	733.8%	337.8%	663.3%	826.4%	759.4%	576.7%	-	325.6%	-	-	38.4%	-	-	
R&D expenses	972	697	828	1,224	1,096	918	849	1,465	857	941	1,176	-	-	
YoY	4.7%	-35.0%	-17.1%	5.8%	12.7%	31.8%	2.5%	19.7%	-21.8%	2.6%	38.5%	-	-	
Other operating expenses	190	172	189	203	343	457	392	415	385	387	442	-	-	
YoY	-12.1%	-5.2%	32.0%	18.4%	80.0%	165.5%	107.4%	103.8%	12.4%	-15.2%	12.8%	-	-	
Operating profit	-1,004	-612	-864	-1,255	-1,249	-1,136	-1,244	-1,857	-1,242	-1,329	-1,617	-	-5,453	
YoY	-	-	-	-	-	-	-	-	-	-	-	-	-	
OPM	-	-	-	-	-	-	-	-	-	-	-	-	-	
Recurring profit	-836	-204	-508	-1,372	-727	-1,312	-1,232	-1,875	-1,506	-1,700	-1,634	-	-5,543	
YoY	-	-	-	-	-	-	-	-	-	-	-	-	-	
RPM	-	-	-	-	-	-	-	-	-	-	-	-	-	
Net income	-838	-204	-508	-1,371	-736	-1,313	-1,232	-1,877	-1,507	-1,700	-1,634	-	-5,544	
YoY	-	-	-	-	-	-	-	-	-	-	-	-	-	
Net margin	-	-	-	-	-	-	-	-	-	-	-	-	-	

Source: Shared Research based on company data

Note: Figures may differ from company data due to differences in rounding methods.

Q3 FY01/21 results

- ▷ Operating loss JPY4.2bn (JPY3.6bn loss in Q3 FY01/20)
- ▷ Recurring loss JPY4.8bn (JPY3.3bn loss in Q3 FY01/20)
- ▷ Net loss* JPY4.8bn (JPY3.3bn loss in Q3 FY01/20)

*Net loss attributable to owners of the parent

- ▷ The company did not generate operating revenue in 1H FY01/21.
- ▷ Operating loss: JPY4.2bn (JPY3.6bn operating loss in Q3 FY01/20). R&D expenses totaled JPY3.0bn (versus JPY2.9bn in Q3 FY01/20) for manufacturing expenses in preparation for applying for approval of the SB623 development program targeting chronic motor deficit from traumatic brain injury (TBI).
- ▷ Non-operating income: Net non-operating expenses expanded from JPY357mn in Q3 FY01/20 to JPY651mn. This is largely attributable to a JPY490mn subsidy income in Q3 FY01/20 and a JPY616mn forex loss recorded in Q3 FY01/21. The forex losses are from foreign currency denominated assets.
- ▷ Recurring loss: Recurring loss widened by JPY1.6bn to JPY4.8bn due mainly to the increase in non-operating expenses.
- ▷ Progress versus forecast: Operating loss stood at 76.8% of recent company full-year forecast while for recurring loss and net loss attributable to owners of the parent the respective rates were both 87.3%.

This note is the most recent addition to the [full report](#).

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at <https://sharedresearch.jp>.

Disclaimer

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by the use of this report.

The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer

The report has been prepared by Shared Research under a contract with the company described in this report ("the company"). Opinions and views presented are ours where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include an opinion from us that could influence investment decisions in the company, such an opinion may be in exchange for consideration or promise of consideration from the company to Shared Research.

Contact Details

Shared Research Inc.

3-31-12 Sendagi Bunkyo-ku Tokyo, Japan

<https://sharedresearch.jp>

Phone: +81 (0)3 5834-8787

Email: info@sharedresearch.jp